Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor-kappaB.
Bradykinin, a mediator of inflammation, is produced in the brain during trauma and stroke. It is thought to open the blood-brain barrier, although the mechanism is unclear. We have investigated, therefore, the effect of bradykinin on the expression of interleukin-6 (IL-6), a putative modulator of the blood-brain barrier, in astrocytes. IL-6 gene transcription was evaluated by transient transfection of the human IL-6 promoter linked to the luciferase gene. In murine astrocytes, bradykinin stimulated IL-6 secretion and gene transcription. The effect of bradykinin was blocked by KN-93, an inhibitor of Ca2+/calmodulin-dependent protein kinases, and by bisindolylmaleimide I, an inhibitor of protein kinase C, suggesting the involvement of these protein kinases. Mutations in the multiple response element and the binding site for nuclear factor-kappaB (NF-kappaB), but not in other known elements of the IL-6 promoter, interfered with induction of IL-6 transcription. The involvement of NF-kappaB was supported further by the finding that overexpression of nmIkappaB alpha, a stable inhibitor of NF-kappaB, inhibited the induction of IL-6 by bradykinin. Bradykinin activated NF-kappaB in primary astrocytes as shown by increased DNA binding of NF-kappaB. These data demonstrate that bradykinin stimulates IL-6 expression through activation of NF-kappaB, which may explain several inflammatory effects of bradykinin.
Schwaninger
M
M
Department of Neurology, University of Heidelberg, Germany.
Sallmann
S
S
Petersen
N
N
Schneider
A
A
Prinz
S
S
Libermann
T A
TA
Spranger
M
M
D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000502:physiology*; D001596:Benzylamines / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology*; D001921:Brain / Q000166:cytology / Q000502:physiology; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D015850:Interleukin-6 / Q000235:genetics*; D007700:Kinetics; D008156:Luciferases / Q000235:genetics; D008301:Maleimides / Q000494:pharmacology; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D011493:Protein Kinase C / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D013449:Sulfonamides / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D019284:Thapsigargin / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D000096926:Benzenesulfonamides
D001596:Benzylamines; D001920:Bradykinin; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D004791:Enzyme Inhibitors; D007211:Indoles; D015850:Interleukin-6; D008156:Luciferases; D008301:Maleimides; D016328:NF-kappa B; D011493:Protein Kinase C; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; D013755:Tetradecanoylphorbol Acetate; D019284:Thapsigargin; C072105:KN 93; D000096926:Benzenesulfonamides; C070515:bisindolylmaleimide I